Public funding highlights Selected developments and initiatives in 2Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...

The mounds of post-market safety data now being generated through social media and other non-traditional data sources are overwhelming regulators and often hindering pharmacovigilance, not improving it. Industry groups have proposed updates to ICH guidelines...

An EU-granted extension for Brexit means short-term clarity for biopharma companies expecting EMA or European Commission decisions before the new Oct. 31 deadline. The U.K. had been scheduled to leave the union Friday. At least...

Although Europe remains at risk of a drug supply disruption in the event of a no-deal Brexit, Thursday's extension means more time for British biopharma companies to get drug applications approved, and for the U.K....

Biopharma groups reiterated that a no-deal Brexit constitutes a real threat to patient safety and public health after the House of Commons' decisive vote against the Withdrawal Agreement for the U.K.'s exit from the EU....

U.K. health and pharma groups are asking their country and the EU to explicitly make cooperation on medicine safety and regulation a priority in the final version of the Political Declaration . The U.K.-EU relationship framework...

With the EU Council's June meeting now completed, the Association of the British Pharmaceutical Industry (ABPI) and the U.K.'s BioIndustry Association (BIA) said there is still no agreement on a deal for life sciences trade...

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...

The European Commission outlined its Horizon Europe research and innovation proposal for 2021-27 on Wednesday, which includes a budget increase to €97.9 billion ($118 billion). The €18 billion (23%) increase over the current Horizon 2020...

The scenario the U.K. is trying to avoid is a full disconnect from EMA when the Brexit curtain falls. But a clean break from the agency could create opportunities for the U.K.’s Medicines and Healthcare...